The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The phase II NIBIT-ML1 study of nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Tumor methylation landscape and correlation with clinical outcomes.
 
Anna Maria Di Giacomo
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Immunocore; Immunocore; MSD Oncology; Pierre Fabre; Sanofi; Sun Pharma
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pierre Fabre
 
Elena Simonetti
No Relationships to Disclose
 
Maura Colucci
No Relationships to Disclose
 
Roberta Depenni
No Relationships to Disclose
 
Raffaella Grifoni
No Relationships to Disclose
 
Monica Valente
Consulting or Advisory Role - Novartis
 
Ramiz Rana
No Relationships to Disclose
 
Maria Lofiego
No Relationships to Disclose
 
Vincenzo D'Alonzo
No Relationships to Disclose
 
Eleonora Carbonari
No Relationships to Disclose
 
Giovanni Amato
No Relationships to Disclose
 
Harold Keer
Employment - Taiho Oncology
 
Aram Oganesian
Employment - Taiho Oncology
 
Danna Chan
Employment - Taiho Oncology
 
Maresa Altomonte
No Relationships to Disclose
 
Diana Giannarelli
Consulting or Advisory Role - Amgen; Sanofi
 
Andrea Anichini
No Relationships to Disclose
 
Michele Ceccarelli
Stock and Other Ownership Interests - Immunomica Srl
Consulting or Advisory Role - Moderna Therapeutics
 
Alessia Covre
Stock and Other Ownership Interests - Epigen Therapeutics, Srl
 
Michele Maio
Stock and Other Ownership Interests - Epigen Therapeutics; Theravance
Honoraria - Alfasigma; Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck; MSD; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Alfasigma; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pierre Fabre; Roche
Patents, Royalties, Other Intellectual Property - DNA Hypomethylating agents for cancer therapy
Travel, Accommodations, Expenses - Alfasigma; Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pierre Fabre; Roche